$14.71
0.41%
Downside
Day's Volatility :2.85%
Upside
2.45%
49.42%
Downside
52 Weeks Volatility :54.33%
Upside
9.7%
Period | Evolus, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 25.83% | 5.1% | 0.0% |
6 Months | -0.54% | 4.9% | 0.0% |
1 Year | 50.1% | 16.6% | 0.0% |
3 Years | 55.33% | 13.2% | -22.3% |
Market Capitalization | 945.2M |
Book Value | $0.31 |
Earnings Per Share (EPS) | -0.88 |
Wall Street Target Price | 22.43 |
Profit Margin | -22.43% |
Operating Margin TTM | -9.11% |
Return On Assets TTM | -9.36% |
Return On Equity TTM | -861.68% |
Revenue TTM | 237.3M |
Revenue Per Share TTM | 4.03 |
Quarterly Revenue Growth YOY | 35.6% |
Gross Profit TTM | 92.7M |
EBITDA | -24.6M |
Diluted Eps TTM | -0.88 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.24 |
EPS Estimate Next Year | 0.16 |
EPS Estimate Current Quarter | -0.05 |
EPS Estimate Next Quarter | -0.1 |
What analysts predicted
Upside of 52.48%
Sell
Neutral
Buy
Evolus, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Evolus, Inc. | 13.94% | -0.54% | 50.1% | 55.33% | -4.04% |
![]() Neurocrine Biosciences Inc. | -16.62% | -11.2% | 10.78% | 28.21% | 20.17% |
![]() Haleon Plc Spon Ads | 7.49% | 20.82% | 28.48% | 39.41% | 39.41% |
![]() Zoetis Inc. | 2.41% | 4.25% | 0.77% | -8.94% | 49.4% |
![]() Viatris Inc. | -0.79% | -8.6% | 12.7% | -23.12% | -31.03% |
![]() Catalent, Inc. | 0.82% | 6.48% | 22.57% | -57.47% | 16.16% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Evolus, Inc. | NA | NA | NA | -0.24 | -8.62 | -0.09 | NA | 0.31 |
![]() Neurocrine Biosciences Inc. | 36.53 | 36.53 | 0.27 | 4.57 | 0.16 | 0.12 | NA | 24.87 |
![]() Haleon Plc Spon Ads | 33.32 | 33.32 | 1.47 | 0.39 | 0.07 | 0.04 | 0.02 | 1.82 |
![]() Zoetis Inc. | 36.6 | 36.6 | 2.61 | 5.82 | 0.49 | 0.14 | 0.01 | 10.94 |
![]() Viatris Inc. | 224.4 | NA | 0.07 | 2.68 | -0.03 | 0.03 | 0.04 | 16.36 |
![]() Catalent, Inc. | 211.02 | NA | 2.87 | 0.2 | -0.25 | 0.0 | NA | 19.91 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Evolus, Inc. | Buy | $945.2M | -4.04% | NA | -22.43% |
![]() Neurocrine Biosciences Inc. | Buy | $12.2B | 20.17% | 36.53 | 16.0% |
![]() Haleon Plc Spon Ads | Buy | $47.1B | 39.41% | 33.32 | 9.66% |
![]() Zoetis Inc. | Buy | $85.7B | 49.4% | 36.6 | 26.29% |
![]() Viatris Inc. | Hold | $13.5B | -31.03% | 224.4 | -4.24% |
![]() Catalent, Inc. | Hold | $10.9B | 16.16% | 211.02 | -23.81% |
Insights on Evolus, Inc.
Revenue is up for the last 2 quarters, 59.33M → 66.90M (in $), with an average increase of 11.3% per quarter
Netprofit is up for the last 2 quarters, -13.10M → -11.35M (in $), with an average increase of 15.5% per quarter
Perceptive Advisors LLC
TANG CAPITAL MANAGEMENT LLC
BlackRock Inc
Morgan Stanley - Brokerage Accounts
Vanguard Group Inc
Nantahala Capital Management, LLC
evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.
Organization | Evolus, Inc. |
Employees | 304 |
CEO | Mr. David Moatazedi |
Industry | Health Technology |
A Spac I Acquisition Corp
$14.71
-1.8%
Keyarch Acquisition Corp
$14.71
-1.8%
Connexa Sports Technologies Inc
$14.71
-1.8%
Us Value Etf
$14.71
-1.8%
First Wave Biopharma Inc
$14.71
-1.8%
Global X Msci Next Emerging
$14.71
-1.8%
Fat Projects Acquisition Corp
$14.71
-1.8%
Capital Link Global Fintech
$14.71
-1.8%
Applied Uv Inc
$14.71
-1.8%